Trial · NCT04347031
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
NCT04347031, Phase 2, Phase 3, Completed, Burnasyan Federal Medical Biophysical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19. Trials, record NCT04347031. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04347031
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
- NCT number
- NCT04347031
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 320 participants, actual
- Lead sponsor
- Burnasyan Federal Medical Biophysical Center
- Conditions
- Pneumonia, Viral, Respiratory Failure
- Interventions
- Mefloquine, Hydroxychloroquine, Mefloquine + azithromycin + / - tocilizumab, Hydroxychloroquine + azithromycin + / - tocilizumab
- First posted
- 2020-04-15
- Last updated
- 2021-01-27
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1st primary endpoint for group 1 | up to 10 days | The number of patients with development of respiratory failure requiring transfer to the ICU. |
| Primary | 2nd primary endpoint for group 1 | up to 10 days | The period of clinical recovery. |
| Primary | 1st primary endpoint for group 2 | up to 10 days | The period of clinical recovery. |
| Primary | 2nd primary endpoint for group 2 | through study completion, an average of 3 months | Frequency of fatal outcomes associated with coronavirus infection disease (COVID19) |
| Secondary | 1st secondary endpoint for group 1 | on days 5 and 10 | A change in viral load by conducting PCR assay through different timeframes |
| Secondary | 2nd secondary endpoint for group 1 | on day 10 | Frequency of clinical cure on day 10 from the start of therapy |
| Secondary | 3d secondary endpoint for group 1 | up to 10 days | The retention time of the reaction temperature from the start of the treatment. |
| Secondary | 4th secondary endpoint for group 1 | up to 10 days | Concentration of C-reactive protein in blood plasma. |
| Secondary | 5th secondary endpoint for group 1 | up to 10 days | Respiratory index. |
| Secondary | 6th secondary endpoint for group 1 | up to 10 days | Frequency appearance unwanted phenomena and serious unwanted phenomena |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04347031
GET https://conductscience.org/api/trials/v1/NCT04347031/registered